Open Access Case Study

A Giant Extraskeletal Chondroma of the Foot: A Case Report

S. Benzarti, M. A. Triki, H. Kaziz, T. Mouelhi, M. L. Ben Ayeche, N. Naouar

International Research Journal of Oncology, Page 1-6

Chondromas and osteochondromas are common benign bone tumors frequently located in the small bones of hands and feet. Extraskeletal chondromas are much rarer and are exceptional if their size exceeds 3 cm.

We report an exceptional case of a giant extraskeletal chondroma of the foot in a 71-year-old man who presented to our outpatient department with a huge mass of the dorsal side of the right foot.

The clinical aspect and the magnetic resonance imaging where suggestive of giant cell tumor of tendon sheath. After a wide surgical excision was performed, the pre-operative findings and histological study suggested otherwise.

Through this case report we discuss the diagnosis issues and the treatment options of extraskeletal chondromas.

Open Access Minireview Article

Cyto-Biological Activities of Lactaptin: An Insight into Designing of New Cancer Therapautics

Idris Zubairu Sadiq

International Research Journal of Oncology, Page 1-7

Background and Objectives: Designing of effective anticancer-based peptides has been challenging these days probably due to the instability of the peptides in serum as well as low sensitivity and resistance of cancer cells to these peptides.

Methodology:  published papers addressing anticancer activity of lactaptin has been reviewed extensively.

Results: Lactaptin, a peptide from proteolytic cleave of kappa casein human milk has been shown to play a number of roles including Program cell death, Genetic material fragmentation, suppression of metastasis, cytotoxicity to the cancer cells as well as caspases activation.

Conclusions: Lactaptin shows promising activity against cancer cells. Accordingly, enhancing lactaptin activity will greatly enhance its therapeutic efficacy and will provide insight into designing of new therapeutics.

Open Access Original Research Article

Hypofractionated Radiotherapy for Localized Prostate Cancer: Clinical Outcome (Mansoura University)

Abeer Hussien Anter, Mohamed Farouk Akl

International Research Journal of Oncology, Page 1-8

Purpose: In this study, we describe the efficacy and safety of hypo fractionated radiotherapy in treating patients with localized prostate cancer.

Patients and Methods: A total of 70 patients diagnosed with localized (T1-T2) prostatic adenocarcinoma. Low and intermediate risk groups were prospectively recruited between November 2012 and November 2016. Patients were treated with hypo-fractionated RT of 60 Gy in 20 fractions over 4 weeks. Androgen deprivation therapy was permitted for intermediate risk patients. The primary outcome was biochemical relapse free survival which defined as the nadir PSA post-radiotherapy plus 2 ng/ml according to PHOENIX criteria. Overall survival and treatment toxicity were secondary end points.

Results: With medium follow-up of 30 months; the three year biochemical relapse-free survival was 93.6%. Acute GU toxicity was detected as follows: 13(18.6%) patients experienced G1 toxicities while 11(15.7%) patients developed G2 toxicities. Acute G1 toxicity was detected with, 11.4% of patients reporting G1 toxicity and 10% experiencing G 2 toxicity. During the follow-up, three patients died; two from systemic disease progression; one patient expired due to cardiac cause. The 5 years overall survival was 90%.

Conclusion: Our data show that a Hypo-RT using 3D-CRT produces an excellent biochemical control and a low incidence of late GI and GU toxicity. Also in absence of IGRT or IMRT, we should use rigid restrictions and adequate margins to get reasonable rate of late toxicity.

Open Access Original Research Article

Depression, Anxiety and Quality of Life of Women with Breast Cancer

Efrossini Lyraraki, Maria Malliarou, Panagiotis Bamidis, Pavlos Sarafis

International Research Journal of Oncology, Page 1-12

Purpose: The primary aim of this research was to detect and to assess anxiety, depression in women with breast cancer undergoing radiotherapy. The study was conducted in the Department of Radiotherapy at the University Hospital of Heraklion, Crete during October 2015 and April 2016.

Methods: A total number of 120 women diagnosed with non-metastatic breast cancer were recruited for this cross-sectional survey. Following informed consent, patients were asked to complete a demographics and clinical data questionnaire comprising with, the Dass-21 scale, the Hospital Anxiety and Depression Scale- HADS. Data was analyzed using IBM SPSS software system.

Results: The incidence of depression and anxiety for breast cancer patients is high. Results highlight similar prevalence of depression with HADS (37.5% mild and moderate depression and 62.5% serious depression) DASS-21 (39.2% mild and moderate 60.8% serious depression) but not similar for anxiety.

Conclusion: The psychological complications in breast cancer patients is remarkable. Efforts to detect and treat depression and anxiety should be a priority, since they contribute to better tolerance and effectiveness in anti-neoplasmatic therapies.

Open Access Original Research Article

Frequency of ABCB1 Polymorphisms in Breast Cancer Patients in South Egypt Cancer Institute by High-Resolution Melting Curve Analysis (Pilot Study)

Hosney Badrway, Abeer Ibrahim, Abeer Mostafa, Dina Ismail Abd El Razik

International Research Journal of Oncology, Page 1-8

Introduction and Aim of the Work: The ABC (ATP-binding cassette) transporter family contributes to the multidrug resistance the genetic variants of this gene have been intensively studied so far.  Some single nucleotide polymorphism (SNPs) of ABCB1 has a correlation with the risk of breast cancer. So this study was conducted to assess value of using of 2 SNPs gene as predicator of risk in Egyptian breast.

Study Design: It is a pilot study to evaluate the value of using 2 SNPs gene as predicator of risk in Egyptian breast.

Patients and Methods: Between September 2016-2017, 50 female breast cancer patients and 20 healthy females control group were included. Peripheral blood samples from patients and control were taken for genomic DNA extraction. And HRM experiment was designed to assess (rs2214102) and (rs2032582) (single nucleotide polymorphism) SNPs of ABCB1 gene this in South Egypt Cancer Institute.

Results: Regarding (rs2214102), all samples have the same heterozygous genotype (GA) with no significant difference between cases and controls. On the other hand, samples of (rs2032582) revealed that samples are divided into 3 groups one is wild homozygous genotype (GG) and other 2 homozygous variants (TT) and (AA). The frequency of the 3 variants in patients and control group showed no statistical difference P=.057.

Conclusion: Using SNPs rs2214102 and rs2032582 are not good predictive factors for breast cancer risk or development.